Impact Investing in Cardiovascular Disease

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Getting Treatments to Patients

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Diversified Portfolio Across Technologies

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

OUR PORTFOLIO

View All

PRESS

Sep 29, 2026
MOSANNA THERAPEUTICS REPORTS POSITIVE RESULTS FROM THE PHASE 1 MOSAIC STUDY OF MOS118 FOR OBSTRUCTIVE SLEEP APNEA
Read More
Sep 23, 2026
Broadview Ventures Announces Promotion of Benjamin Kreitman to Associate Director
Read More
Aug 25, 2026
Basking Biosciences Announces Positive Topline Phase 1 Data for BB-025, the Reversal Agent for its Acute Ischemic Stroke Thrombolytic Therapy BB-031
Read More
Jul 28, 2026
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
Read More
View All